Atezolizumab

BNF:
Not listed
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED:

  • NICE TA492for untreated PL-L1-postive locally advanced or metastatic urothelial cancer in patients where cisplatin is unsuitable.  (Decision date - January 2018).
  • NICE TA520: for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy.  (Decision date - June 2018).
  • NICE TA525: for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.  (Decision date - July 2018).
  • NICE TA584: in combination for treating metastatic non-squamous non-small-cell lung cancer.  (Decision date - July 2019).
  • NICE TA638: with carboplatin and etoposide for untreated extensive stage small cell lung cancer.  (Decision date - August 2020).
  • NICE TA639: with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer.  (Decision date - August 2020).
  • NICE TA666: with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. (Decision date - January 2021).
  • NICE TA705: monotherapy for untreated advanced non-small-cell lung cancer.  (Decision date - July 2021).
  • NICE TA739: for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable.  (Decision date - Nov 2021).
  • NICE TA823: for adjuvant treatment of resected non-small-cell lung cancer.  (Decision date - October 2022).

DNP:

  • NICE TA618 - with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer.  (Terminated appraisal) (Decision date - February 2020).

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app